Ruxolitinib tablets/ruxolitinib usage, dosage and precautions

Ruxolitinib tablets/ruxolitinib (JAKAVI) is an oral small molecule drug that acts on two tyrosine kinases, JAK1 and JAK2. It is widely used in the treatment of myeloproliferative diseases such as polycythemia vera (PV), primary myelofibrosis (PMF) and secondary myelofibrosis (sMF). By inhibiting the JAK-STAT pathway, it regulates cytokine signaling to inhibit abnormal hematopoiesis, improve splenomegaly and systemic symptoms.

The dose of ruxolitinib needs to be individually adjusted based on the specific indication, patient weight and blood cell count levels. The usual starting dose is oral administration twice a day ranging from 5 mg to 20 mg. It is recommended to take it with or without food, but it should be taken within a roughly fixed time every day to maintain stable blood concentration. Dose adjustment should be based on dynamic monitoring of the patient's platelet count, neutrophil level, liver and kidney function, and regular blood routine review to assess the risk of myelosuppression.

The most common adverse reactions with ruxolitinib include anemia, thrombocytopenia, and neutropenia. In order to reduce the occurrence of such myelosuppressive side effects, it is recommended to closely monitor blood levels before and during the initial treatment, and adjust the dose or even suspend treatment if necessary. Anemia may worsen in the early stages of treatment, but some patients can gradually stabilize in the later stages. In addition, the risk of infection also needs attention, including bacterial, viral and even fungal infections, especially those with a history of previous infections or who are immunosuppressed.

Ruxolitinib is metabolized by the liver, mainly through the CYP3A4 enzyme pathway, so interactions with other drugs also need to be paid attention to. Concomitant use with strong CYP3A4 inhibitors (such as ketoconazole) or inducers (such as rifampicin) should be avoided. If combined use is necessary, the dose of ruxolitinib needs to be adjusted appropriately based on the pharmacokinetic characteristics. In addition, in patients with hepatic or renal impairment, the starting dose should be reduced and treatment response closely monitored.

Reference materials:https://www.jakavi.com/